Serosal penetration is an important prognostic factor for gastrointestinal stromal tumors

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 779-783

  Vallbohmer D ^a   Marcus, H E ^a   Baldus, S E ^b   Brabender, J ^a   Drebber, U ^a   Metzger, R ^a   Holscher A H ^a   Schneider, Paul M ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Gastrointestinal stromal tumors; Prognostic factors; Serosal penetration

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; SEROSA; SURVIVAL TIME; TUMOR CLASSIFICATION; TUMOR VOLUME;

ADULT; AGED; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 54949086709     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000074     Document Type: Article

References (14)

1. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459-465,2002.
2. Franquemont DW: Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 103: 41-47, 1995.
3. Miettinen M, El-Rifai W, Sobin LH and Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33: 478-483, 2002.
4. Emory TS, Sobin LH, Lukes L, Lee DH and O'Leary TJ: Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site. Am J Surg Pathol 23: 82-87, 1999.
5. Tornoczky T, Kover E and Pajor L: Frequent occurrence of low grade cases among metastatic gastrointestinal stromal tumours. J Clin Pathol 56: 363-367, 2003.
6. Bollschweiler E, Baldus SE, Schroder W, Prenzel K, Gutschow C, Schneider PM and Hölscher AH: High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy 38: 149-156, 2006.
7. Takashima S and Kosaka T: Results and controversial issues regarding a para-aortic lymph node dissection for advanced gastric cancer. Surg Today 35: 425-431, 2005.
8. Compton CC: Colorectal carcinoma: diagnostic, prognostic and molecular features. Mod Pathol 16: 376-388, 2003.
9. Yan H, Marchettini P, Acherman YI, Gething SA, Brun E and Sugarbaker PH: Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 26: 221-228, 2003.
10. Rubin BP, Heinrich MC and Corless CL: Gastrointestinal stromal tumour. Lancet 369: 1731-1741, 2007.
11. DeMatteo R, Owzar K, Maki R, et al and the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST study team: Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25: 10079, 2007.
12. Heinrich MC, Corless CL, Blanke CD, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764-4774, 2006.
13. Andersson J, Bumming P, Meis-Kindblom JM, et al: Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130: 1573-1581, 2006.
14. Wong NA, Young R, Malcomson RD, et al: Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 43: 118-126, 2003.